Strategic advancements in targeting the PI3K/AKT/mTOR pathway for Breast cancer therapy

Breast cancer (BC) is a complex disease that affects millions of women worldwide. Its growing impact calls for advanced treatment strategies to improve patient outcomes. The PI3K/AKT/mTOR pathway is a key focus in BC therapy because it plays a major role in important processes like tumor growth, survival, and resistance to treatment. Targeting this pathway could lead to better treatment options and outcomes. The present review explores how the PI3K/AKT/mTOR pathway becomes dysregulated in BC, focusing on the genetic changes like PIK3CA mutations and PTEN loss that leads to its aggravation. Current treatment options include the use of inhibitors targeting PI3K, AKT, and mTOR with combination therapies showing…

• UD
  U.S. Department of Defense

  Awards: HT9425-23\u20131-0581, W81XWH-22\u20131-0331, PC240476, W81XWH-16\u20131-0641
• NI
  National Institutes of Health

  Award: P30CA33572
• NC
  National Cancer Institute